ZuriEV Company
ZuriEV is a University of Zurich spin-off developing a highly sensitive, non-invasive blood-based diagnostic platform for early detection and monitoring of brain cancers. Their liquid biopsy technology isolates tumor-specific extracellular vesicles (EVs) from blood using proprietary biomarkers, enabling accurate and scalable cancer detection and monitoring.
Headquarters:
Zürich, Zurich, Switzerland, Europe
Industry:
Biomarkers & Liquid Biopsy
Super Industry:
Diagnostics & Genomics
Investors:
Venture Kick
Ipo Status:
private
City:
Zürich
Region:
Zurich
Country:
Switzerland